Associated Papers
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
Nesic K et al.
Molecular Cancer, 2024
39103848 (PubMed )
Supplement: 12943_2024_2048_MOESM1_ESM.xlsx › Table_S5_-_NGS_data
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
Nesic K et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
36993400 (PubMed )
Supplement: media-1.xlsx › Table_S5_-_BROCA_data
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.
Ho GY et al.
Therapeutic Advances in Medical Oncology, 2023
38028140 (PubMed )
Supplement: sj-xlsx-2-tam-10.1177_17588359231208674.xlsx › Supp_Table_S2
The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.
Meisel JL et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2014
Select a paper to view details